

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6564420

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
HERRIOT TABUTEAU	11/24/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	AXSOME THERAPEUTICS, INC.
<b>Street Address:</b>	22 CORTLANDT STREET, 16TH FLOOR
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10111
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17119792
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(435)252-1361
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	949-202-1900
<b>Email:</b>	Docket@mabr.com
<b>Correspondent Name:</b>	BRENT A. JOHNSON
<b>Address Line 1:</b>	MASCHOFF BRENNAN
<b>Address Line 2:</b>	100 SPECTRUM CENTER DRIVE, SUITE 1200
<b>Address Line 4:</b>	IRVINE, CALIFORNIA 92618
<b>ATTORNEY DOCKET NUMBER:</b>	A3225.10019US13
<b>NAME OF SUBMITTER:</b>	MARIA NADAL
<b>SIGNATURE:</b>	/Maria Nadal/
<b>DATE SIGNED:</b>	02/22/2021
<b>Total Attachments: 7</b>	
source=A3225.10019US13 - EXECUTED ASSIGNMENT PARENT#page1.tif	
source=A3225.10019US13 - EXECUTED ASSIGNMENT PARENT#page2.tif	
source=A3225.10019US13 - EXECUTED ASSIGNMENT PARENT#page3.tif	
source=A3225.10019US13 - EXECUTED ASSIGNMENT PARENT#page4.tif	
source=A3225.10019US13 - EXECUTED ASSIGNMENT PARENT#page5.tif	

source=A3225.10019US13 - EXECUTED ASSIGNMENT PARENT#page6.tif

source=A3225.10019US13 - EXECUTED ASSIGNMENT PARENT#page7.tif

## ASSIGNMENT

**THIS ASSIGNMENT** is made by **Herriot Tabuteau** (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNOR") to **Axsome Therapeutics, Inc.**, a legal entity having its principal place of business at 22 Cortlandt Street, 16<sup>th</sup> Floor, New York, New York 10007 (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNEE").

**WHEREAS**, ASSIGNOR has invented and owns rights in, to and under new and useful inventions for which an application(s) for or Letters Patent has been filed as indicated on **Exhibit A** (hereafter "Inventions");

**WHEREAS**, ASSIGNOR believes himself to be the original and true inventor of the Inventions;

**WHEREAS**, ASSIGNEE desires to acquire the Inventions and improvements thereto;

**AND WHEREAS**, ASSIGNOR and ASSIGNEE desire to have a recordable instrument assigning ASSIGNEE as owners of the entire right, title and interest in, to, and under the Inventions and improvements thereto owned by ASSIGNOR;

**NOW THEREFORE**, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign, transfer, convey, endorse, and hereby set over unto ASSIGNEE the full and exclusive right, title and interest in, to and under the Inventions to be held and enjoyed by ASSIGNEE, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made including the full and exclusive right, title and interest in, to and under 1) any patent application, or any other legal instrument equivalent thereof, including, without limitation, continuation, division, continuation-in-part, substitute, reexamination, renewal, inventor's certificate, and utility model, which has been or may be submitted therefor and thereon anywhere in the World, such term defined herein as including the United States of America, its territorial possessions, and any and all foreign countries under national laws or under the provisions of the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or any other international treaty equivalent thereof; 2) any Letters Patent, or any other legal instrument equivalent thereof, which has been or may be granted therefor and thereon, in the World, for the full term or terms for which the same may be granted; 3) any reissue, extension, or any other legal instrument equivalent thereof, on any patent application or Letters Patent which has been or may be granted therefor and thereon in the World; and 4) any right to claim priority to a filing date, or any other legal equivalent thereof, which has been or may be claimed by any patent application or Letters Patent therefor and thereon in the World.

**ASSIGNOR** hereby covenants and agrees to perform any lawful action when deemed essential by and to ASSIGNEE's full enjoyment, protection, enforcement and title in, to and under the Inventions and rights hereby transferred, including, but not limited to, promptly communicating and providing any and all known and accessible facts, data or any other pertinent information; promptly executing and delivering any and all papers, documents, forms, declarations, oaths, affidavits or any other legal instrument; promptly assisting and participating in any and all depositions, hearings, proceedings, trials, appeals, or any other legal procedure; promptly testifying under oath in any and all interference, post grant review, litigation or any other

administrative or judicial proceeding; and promptly completing any and all actions necessary or desirable to carry out any and all purposes thereof, relating to any and all proceedings in connection with the submission, procurement, issuance, maintenance, enforcement or defense of the inventions and rights hereby transferred.


The undersigned hereby grant to the firm of Maschoff Brennan, 100 Spectrum Center Drive, Suite 1200, Irvine CA 92618, the power to insert in this Assignment any further information, such as the application number, which may be necessary or desirable for identification of the Inventions and/or for recordation of this Assignment.

*A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.*

**IN TESTIMONY WHEREOF**, I hereunder set my hand this 24 day of Nov., 2020.

**ASSIGNOR**


**Herriot Tabuteau**

  
\_\_\_\_\_  
Signature

State of NEW YORK )  
County of New York ) ss.:

On this 24 day of Nov, 2020, before me, Neil Schneider, personally appeared **Herriot Tabuteau**, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.

  
\_\_\_\_\_  
Notary Public


NEIL SCHNEIDER  
NOTARY PUBLIC-STATE OF NEW YORK  
No. 01SC6065135  
Qualified in New York County  
My Commission Expires 10-09-2021

*A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.*

**ACKNOWLEDGED AND CONFIRMED**, I hereunder set my hand this 24 day of Nov., 2020, as a duly authorized representative of ASSIGNEE.

**ASSIGNEE**

**Axsome Therapeutics, Inc.**


  
Name: Herriot Tabuteau, MD  
Title: CEO

State of NEW YORK        )  
County of New York    )

ss.:

On this 24 day of Nov, 2020, before me, Neil Schneider, personally appeared **Herriot Tabuteau** who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.

  
\_\_\_\_\_  
Notary Public

NEIL SCHNEIDER  
NOTARY PUBLIC-STATE OF NEW YORK  
No. 01SC8066136  
Qualified in New York County  
My Commission Expires 10-09-2021

**EXHIBIT A**

<b><u>Title</u></b>	<b><u>Serial No.</u></b>	<b><u>Filing Date</u></b>
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	16/806,145	03/02/2020
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	16/807,512	03/03/2020
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	62/992,060	03/19/2020
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	16/830,637	03/26/2020
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	16/832,153	03/27/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/834,077	03/30/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/835,848	03/31/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/837,769	04/01/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	63/006,023	04/06/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/841,436	04/06/2020

<b><u>Title</u></b>	<b><u>Serial No.</u></b>	<b><u>Filing Date</u></b>
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/842,063	04/07/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/843,490	04/08/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/844,634	04/09/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/854,320	04/21/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/857,435	04/24/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/867,929	05/06/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/885,975	05/28/2020
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	16/907,691	06/22/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/921,006	07/06/2020
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	16/923,420	07/08/2020

<b><u>Title</u></b>	<b><u>Serial No.</u></b>	<b><u>Filing Date</u></b>
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	16/924,510	07/09/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/927,623	07/13/2020
METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION	16/931,907	07/17/2020
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION	PCT/US2020/046755	08/18/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/997,740	08/19/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	16/998,622	08/20/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	17/016,172	09/09/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	17/018,275	09/11/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	17/021,131	09/15/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	17/024,233	09/17/2020



<b><u>Title</u></b>	<b><u>Serial No.</u></b>	<b><u>Filing Date</u></b>
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	63/083,040	09/24/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	17/064,016	10/06/2020
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	17/067,006	10/09/2020
USE OF REBOXETINE TO TREAT NARCOLEPSY	PCT/US20/62560 of US 62/943,077 and 62/946,295	11/30/2020
COMBINATION TREATMENT FOR MIGRAINE AND OTHER PAIN	PCT of US 62/955,905	12/29/2020